Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors TF Hickish', IE Smith2, MER O'Brien2, S Ashley2 and G Middleton2 'Royal Boumemouth Hospital, Castle Lane East Boumemouth, Hampshire BH7 7DW, UK: 2Lung Unit, Royal Marsden NHS Trust. Downs Road. Sutton. Surrey SM2 5PT, UK Summary The intention of this study was to identify the pretreatment characteristics predicting for the survival, objective response and symptom relief in patients with non-resectable, non-small-cell lung cancer (NSCLC) managed in the Lung Unit at the Royal Marsden Hospital. This analyss induded 290 patients with advanced NSCLC generally treated with a cisplatin-based chemotherapy regimen in one of a series of trials. Thirty-seven pretreatment variables, response and survival data were collected prospectvely and analysed using univariate and muftivanate methods. By muttivariate analysis perforrance status, disease extent and pattem of metastases ak)ng with certain biocemnical features were influential independent variables for survival, objective and symptom response. Older age was positively associated with objecive response (P= 0.04). When the independent factors for symptom response were used to group patients into prognostic categories, 30P480/o of patients with an adverse set of factors had symptom relief. Similarly using the relative risk of death to subgroup the patient population, 54% of patients at high risk of death (greater than 8.0), with a median survival of 2.5 months, had symptom relief. The data are consistent with other studies in identifying the pretreatnent factors predicting for survival and objective response. Additionally, older age is positivety associated with objective response and the majority of patents with the worst prognosis have symptom relief from treatment with chemotherapy.
The prognosis of advanced inoperable non-small-cell lung cancer is poor and the use of chemotherapy to palliate this disease remains controversial. although evidence is accumulating that demonstrates that its use is associated with symptom relief. a small survival advantage and perhaps economic benefit (Jaakkimainen et al. 1990 : Cullen. 1993 : Souquet et al. 1993 : Ellis et al. 1995a : Non-small Cell Lung Cancer Collaborative Group. 1995 . Platinum-based chemotherapy regimens. usually combined with the vinca alkaloids. have resulted in reproducible objective response rates of the order of 30% (Veronesi et al. 1988 : Luedke et al. 1990 : Donnadieu et al. 1991 . A series of retrospective analyses of clinical trials of chemotherapy in advanced NSCLC have identified a range of factors predicting for survival and response (O'Connell et al. 1986 : Kawahara et al. 1991 : Weick et al. 1991 : Shinkai et al. 1992 : Paesmans et al. 1995 . with the intention of designing better randomized trials that might detect only small survival improvements. Currently available cytotoxic chemotherapy. however. is used as a palliative intervention in advanced NSCLC. and it is therefore important to know which pretreatment characteristics might influence the likelihood of symptomatic benefit in addition to any influence on response and survival.
Since 1990. we have prospectively generated a database of patients with a diagnosis of advanced. inoperable NSCLC referred Tables 1 and 2 . Patients received chemotherapy according to the following regimens: MVP (mitomycin C. vinblastine and cisplatin) (Ellis et al. 1995a (Table 3) .
Patients received supportive care as appropriate with steroids. analgesia. pleural effusion drainage ± pleuradesis. radiotherapy and counselling. Twenty-six patients had received palliative radiotherapy (generally to lung. bone or CNS). less than 3 months (and more than 1 week before) commencing chemotherapy. Fourteen patients had previously been exposed to non-cytotoxic systemic (12) 103 (35) 187 (65) 30 (10) 196 (68) 40 (14) 10 (3) 193 (67) 40 (14) 29 (10) 28 (9) 18 (6) 272 (94) 59 (20) 231 (80) 15 (5) 275 (95) 80 (28) (Miller et al. 1981) . Symptom response was recorded as follows. Tumour-related symptoms were recorded at the start of treatment under the following general headings: malaise, pain. cough, dyspnoea or 'other' which was then specified. Symptoms were then reassessed after each course of treatment with patients asked to grade change in symptoms by a nurse specialist using simple descriptive critenra as follows: (1) Objective response Thirty-seven pretreatment factors (Tables 1 and 2) were included in the univariate analysis for objective response. Only three were found to be associated with objective response. Combination vs single-agent chemotherapy. limited vs extensive disease and performance status (ECOG) each significantly predicted for a response (P < 0.05). In the multivariate analysis (Table 4) . performance status had independent significance for predicting response (P = 0.006). Additionally. one lung, as opposed to both lungs. involved predicted for response (P= 0.005). Increasing age positively predicted for response (P = 0.04).
Symptom response
Of the patients. 270 were evaluable for symptom response. In the univariate analysis. male sex. disease extent (limited vs extensive) (P < 0.05), performance status (P < 0.05) and the absence of prior radiotherapy (P < 0.05) were all positive predictors for response. The absence of skin involvement (P < 0.05) and the absence of CNS involvement (P < 0.05) were also positive predictors of response. Raised calcium (corrected > 2.6 mmol 1-1) was a predictor for symptomatic response (P < 0.05). In the multivariate analysis for symptom response. the variables analysed were those used in the objective response analysis (Table 4) . excluding individual symptoms. CNS involvement (P = 0.007). poor performance status (P = 0.004). skin involvement (P = 0.03) and bilateral lung involvement (P = 0.03) were independent adverse predictors for symptomatic response to chemotherapy (Table 4 ). The multiplicative nature of relative likelihoods enabled the calculation of a prognostic index. for each patient. based on the significant independent predictors of symptom relief. This index was used to divide patients into prognostic groups with differing likelihoods of symptom response. For simplicity of calculation in the clinic, an equivalent definition of the prognostic groups used the number of poor prognostic factors that they had, as follows: performance status 2 scores 1. performance status 3 scores 2: involvement of CNS scores 2: involvement of skin scores 2: involvement of both lungs scores 1 (Table 5 ). This analysis indicates that 30-48% of patients with an adverse set of prognostic factors for symptom response will yet have such a response.
Survival
In the univariate analysis. male sex (P < 0.025). extensive disease status (P < 0.005). low performance status (P < 0.005) and previous radiotherapy (P < 0.01) predict for poorer survival. Similarly. involvement of both lungs (P < 0.05). skin involvement (P < 0.005), bone involvement (P < 0.005) and adrenal involvement (P < 0.05) have poorer survival. The following biochemical variables also predicted for poor survival: serum albumin < 35 g 1-1 Table 3 Chemotherapy regimens (P < 0.005). sodium < 135 mmol 1-' (P < 0.005). alkaline phosphatase elevated more than two times the normal level (P < 0.005). alanine transaminase elevated more than two times the normal level (P < 0.025). haemoglobin < 13 g (P < 0.05) and reduced white cell count <8.0 x 10 (P < 0.005). In the multivariate analysis (Table 4) . poorer perfonnance status (P < 0.001). alkaline phosphatase elevated more than two times the normal level (P < 0.001). extensive disease (P < 0.001). albumin < 35 g 1-' (P = 0.01) and skin involvement (P < 0.025) were all predictors of poorer survival. For a patient with two or more poor prognostic features. the relative risks of death are multiplicative. The overall risk of death. relative to a patient with no poor prognostic features. was calculated for each patient and was used to group the patients into prognostic groups. Patients with an overall risk of death of less than 4.0 had the best prognosis. with a median survival of 9 months. an objective response rate of 37% and a symptomatic response rate of 78%. Those patients with a relative risk of death between 4.0 and 8.0 had an intermediate prognosis. with a median survival of 6 months. an objective response rate of 39% and a symptomatic response rate of 77%. Those with the worst prognosis and a relative risk of death greater than 8.0 had a median survival of 2.5 months, an objective response rate of 13% but a symptomatic response rate of 54% (Table 6 ).
DISCUSSION
Consistent with previous reports on prognostic factors in advanced NSCLC (Albain et al. 1991 : Paesmans et al. 1995 . multivariate analysis in this trial identified performance status as a key factor adversely influencing survival. as was an elevated alkaline phosphatase. the presence of extrathoracic disease and the presence of skin metastases. All of these factors had been found to adversely influence survival in other studies but. other than performance status, they are not reproducibly influential. This also holds for the factors influencing objective response.
In this study. again. poor performance status adversely influenced the likelihood of a response. as did the presence of bilateral lung involvement. Increasing age was, perhaps surprisingly. found to positively predict for response. This positive influence of age on outcome to chemotherapy in advanced NSCLC was also detected by Albain et al (1991) . when age was found to positively predict for increased survival. Furthermore. in our study. by multivariate analysis. age had no influence. either positive or negative. on symptom relief or survival.
In our multivariate analysis. poorer performance status, the presence of CNS. skin and bilateral lung involvement adversely predicted for symptomatic response. However. when patients were grouped by the number of factors adversely predicting symptom response. even those with the highest score still had a 30% probability of a symptomatic response.
Taking together the factors identified by multivafiate analysis to influence objective response, symptomatic response and survival. those patients with the greatest relative risk of death (> 8.0) had a very poor mean survival of 2.5 months and a very small chance of objective response (13%) but still had a reasonable probability of a symptomatic response (54%), with significant alleviation in all the recorded symptoms. Accurate quantification of the symptom relief benefit resulting from chemotherapy can only be provided by a placebo-controlled randomized trial in which all patients receive optimal supportive care. Clearly, in this study, supportive care therapies will have influenced symptomatology. However, given that the vast majority of patients are established on appropriate supportive care at presentation, it seems likely that these measures would dilute only. rather than fully account for. symptom relief associated with chemotherapy.
An important finding in this analysis is that age is not an adverse factor in the palliation of NSCLC. and yet such treatment is usually reserved for younger age groups. The upper age limit in only four of eight authoritative trials of chemotherapy vs supportive care for patients with advanced NSCLC extended to 75 years (reviewed in Shepherd. 1994) , and the average of the median ages in this group of trials was approximately 60 years. There was no evidence from these trials that the elderly fared less well with chemotherapy. The impact of age as a prognostic factor for survival and response in advanced NSCLC has been analysed in a series of recent reports totalling 4516 patients (O'Connell et al. 1986; Albain et al, 1991 : Kawahara et al, 1991 Shinkai et al, 1992; Paesmans et al, 1995) . In one of these. the South West Oncology Group analysed a database of 2531 patients with stage IV NSCLC (Albain et al, 1991) and found by multivariate analysis that age greater than 70 years was in fact a significant independent positive predictor for survival (P = 0.02). In the remainder of these studies, age had no influence by multivariate analysis. Given that more that 50% of patients with advanced NSCLC are over the age of 65 years and the growing elderly population, palliative treatment of the elderly with this disease is likely to be a growing issue, and our data indicate that such patients should not be excluded from palliative chemotherapy trials on the grounds of age alone. Performance status, irrespective of age, would seem to be a much more appropriate basis for treatment selection.
In summary, this analysis of a large database of patients treated in a series of clinical trials demonstrates that even patients with the worst outlook are likely to benefit from palliation with chemotherapy and that age is not an adverse prognostic factor.
